Genesis. Author manuscript; available in PMC 2009 Jul 10.
Published in final edited form as:
PMCID: PMC2708938
NIHMSID: NIHMS128325
Department of Developmental Biology and Kent Waldrep Foundation Center for Basic Neuroscience Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, Texas
Jian Chen and Chang-Hyuk Kwon contributed equally to this work.
To establish a genetic tool for manipulating the neural stem/progenitor cell (NSC) lineage in a temporally controlled manner, we generated a transgenic mouse line carrying an NSC-specific nestin promoter/enhancer expressing a fusion protein encoding Cre recombinase coupled to modified estrogen receptor ligand-binding domain (ERT2). In the background of the Cre reporter mouse strain Rosa26lacZ, we show that the fusion CreERT2 recombinase is normally silent but can be activated by the estrogen analog tamoxifen both in utero, in infancy, and in adulthood. As assayed by -galactosidase activity in embryonic stages, tamoxifen activates Cre recombinase exclusively in neurogenic cells and their progeny. This property persists in adult mice, but Cre activity can also be detected in granule neurons and Bergmann glia at the anterior of the cerebellum, in piriform cortex, optic nerve, and some peripheral ganglia. No obvious Cre activity was observed outside of the nervous system. Thus, the nestin regulated inducible Cre mouse line provides a powerful tool for studying the physiology and lineage of NSCs.
Keywords: Cre-ERT2, nestin, neural stem cells, tamoxifen, transgenic mouse, recombination
The recognition that the adult brain retains stem cells (NSCs) has fundamentally changed our view of brain plasticity (Lie et al., 2004; Ming and Song, 2005; Zhao et al., 2008). It also raises the hope of cell replacement therapy for neurodegenerative disease (Lie et al., 2004). Adult neurogenesis in the subventricular zone (SVZ) of the lateral ventricles serves to replenish olfactory bulb (OB) interneurons via the rostral migratory stream (RMS). In the dentate gyrus, neurogenesis in the subgranular layer (SGL) generates synaptically active granule neurons and has been implicated in learning, memory and mood disorders in rodents (Li et al., 2008; Ming and Song, 2005; Zhang et al., 2008; Zhao et al., 2008). The development of conditional mutant alleles using the Cre/loxP system has permitted circumvention of early lethality observed when many genes are mutated by traditional knockout, thus offering the opportunity to study gene function with spatial control (Mak, 2007). A further refinement of this technology has been the development of inducible Cre transgenes that permit temporal control of gene recombination and inactivation (Feil et al., 1997; Hayashi and McMahon, 2002). Fusion of the Cre recombinase protein with a modified estrogen receptor ligand-binding domain (ERT2) causes sequestering of the fusion protein in the cytoplasm where it cannot mediate loxP recombination. Application of estrogen or estrogen analogs, however, causes translocation of the Cre-ERT2 fusion protein to the nucleus where recombination can then be achieved.
To achieve temporal ablation of genes in the neural stem cell lineage, we have constructed a tamoxifen-inducible Cre transgene that is regulated by the neurogenic lineage specific promoter/enhancer of the nestin gene. Nestin is an intermediate filament protein specifically expressed in neural stem/progenitor cells in both developing central nervous system and adult brain. The regulatory element driving neural-specific nestin expression has been mapped to the second intron of the nestin gene (Lendahl et al., 1990; Zimmerman et al., 1994). As detailed in our studies, we show that the transgene is silent in the absence of estrogen analog. Upon activation, the expression is robust and recombination is elicited primarily in the principal neurogenic niches. Additional expression is confined to the cerebellum, certain peripheral nerves, and to the piriform cortex, a potentially novel site of neurogenesis.
The Cre-ERT2 cDNA was placed under the control of a 5.6 kb rat nestin 5 regulatory element and followed by the 668 bp of inversed nestin second intron (). Six transgenic lines were obtained after pronuclear injection and four underwent germline transmission. To assay Cre recombinase activity after induction, we crossed the CreERT2 lines with Rosa26-stop-lacZ (Rosa26lacZ) reporter mice. The Rosa26lacZ mice require Cre-mediated recombination for -galactosidase gene activation due to a stop cassette flanked by loxP sites upstream of the lacZ gene. To assess inducibility of the Cre transgene, sunflower oil vehicle (150 l) or the estrogen analog tamoxifen (1 mg) was injected into pregnant mice at embryonic day 12.5 (E12.5) and the embryos were dissected out at E14.5 for whole mount X-gal staining. In a Rosa26lacZ reporter background, exposure of the four transgenic lines to tamoxifen revealed that only two of the lines (Line 8 and Line 73) exhibited recombination activity ( and not shown). Moreover, comparison of Cre activity upon induction was similar although Line 8 was leaky, having minor but detectable Cre activity in the absence of tamoxifen. In contrast, Line 73 (Nes73-CreERT2) showed no signs of Cre activity in the absence of tamoxifen and the blue X-gal staining was found predominantly in embryonic brain and spinal cord where most nestin-positive neural progenitors are located ().
Transgene construct and tamoxifen inducibility. (a) Structure of the Nestin-CreERT2 transgene consisting of the rat nestin promoter/enhancer, cDNA encoding the CreERT2 fusion protein and inversely oriented Nestin second intron. (b) Transgene induction ...
The temporal control of Cre activity allowed us to induce Cre-mediated recombination for the purpose of tracing NSCs and their progeny at various time points. The pattern observed upon embryonic induction closely reflected the course of brain development. Tamoxifen induction at E13.5 labeled almost the entire cortex in the forebrain as well as the entire cerebellum including neurons and glia (). This coincides with the initiation of neural progenitor migration that contributes to different cortical layers in embryonic neural development (Sun et al., 2002). Induction at E17.5, when neurogenesis in the forebrain reaches completion, resulted in labeling of only the outer most layers of the cortex (), which stands in line with the inside-out pattern of cortex layer formation (Sun et al., 2002). Additionally, the thalamus and hindbrain were labeled at this time point. In the neonatal mouse brain, there is persistent mild but widespread lacZ activity, indicative of residual but rare progenitor cells throughout the parenchyma (). The most active neurogenic region at this time is the cerebellum (Herrup and Kuemerle, 1997), which showed intense lacZ staining following induction at E17.5 through P7 (). Mouse cerebellum development is considered to be complete by 3 weeks after birth, however our Nes73-CreERT2;Rosa26lacZ mice showed strong Cre activity in the anterior part of cerebellum when induced 4 and 8 weeks after birth (, and ; and see below). Nonetheless, in the anterior brain, by 4 weeks of age the SVZ and SGL are the most neurogenic regions as assayed by tamoxifen-induced Cre activity ().
Novel Cre activity. Nes73-CreERT2;Rosa26lacZ mice were treated with tamoxifen at 4 weeks of age and analyzed at 8 weeks (ac, eh, left and right panel of i). Abundant -Gal expression was detected in the anterior part of cerebellum ...
Adult NSCs modify their gene expression as they migrate and differentiate. In the SVZ, glial fibrillary acidic protein (GFAP) positive cells are considered to be stem cells (Doetsch et al., 1999). When differentiation starts and neuronal fate of the progenitor cells has been specified, cells begin to express doublecortin (DCX) and migrate into the OB through the RMS to finally become NeuN-positive mature neurons (Doetsch et al., 1999; Ming and Song, 2005). To determine the sites of primary Cre recombinase activity, we examined the SVZ of 4-week-old Nes73-CreERT2;Rosa26lacZ mice 48 h after a short pulse of tamoxifen, since both GFAP-positive neural stem cells and some transient amplifying progenitor cells express nestin. X-gal staining followed by immunohistochemistry (IHC) with GFAP or DCX antibody revealed that the majority of Cre activity resides in GFAP-positive SVZ cells close to the lateral ventricle, with only rare DCX-positive SVZ or RMS cells showing recombination (). This was further confirmed using an estrogen receptor antibody to show double labeling of Cre-ERT2-positive cells with the stem cell marker GFAP, and with S100, a marker of radial glia-derived ependymal cells (Supp. Info. Fig. 1) (Spassky et al., 2005). These studies indicate that the primary site of tamoxifen-activated Cre recombinase is the GFAP-positive, SVZ stem cell population.
Cre activity in adult NSC niches and migration targets. (a) Representative X-gal stained brain sections from mice 48 h after two tamoxifen administrations at P28 (12-h interval). X-gal signal was mainly restricted to SVZ (a1), with little or no signal ...
To measure the efficiency of tamoxifen-induced recombination in our Nes73-CreERT2 mice, we crossed them with the Rosa26YFP reporter line to generate Nes73-CreERT2;Rosa26YFP mice and then induced these mice with tamoxifen at 4 weeks of age. We then harvested brain sections from the induced mice at 6 weeks of age, and performed immunofluorescent double-labeling with GFP and Sox2 antibodies (Supp. Info. Fig. 2). The percentage of GFP/Sox2 double-positive cells divided by the number of Sox2 positive cells in the SVZ was used to determine recombination efficiency. This quantification analysis revealed that 75 4% of Sox2-positive cells in the SVZ have been targeted 2 weeks after a 5-day tamoxifen induction.
To further study the dynamics of stem/progenitor cell migration and differentiation, Nes73-CreERT2;Rosa26lacZ mice were induced at 4 weeks of age and examined by X-gal staining 2 or 4 weeks later ( and ). The dynamics of Cre-active cells in the hippocampus over time was not very dramatic (), however in the SVZ, an increase in the number of Cre active cells in an expanded ventricular area was evident 4 weeks after induction (). These results suggest a precursor-progeny relationship in which, after 2 weeks of induction, a significant number of new progenitor cells have been generated by stem cells and are beginning to disperse from the SVZ. Similarly, in the OB 2 weeks after induction, the X-gal positive cells were confined to a central cluster, whereas 4 weeks postinduction the cells were dispersed throughout the OB (). We interpret this result to indicate that at 2 weeks postinduction, cells are just arriving to the OB via the RMS and are confined to this central area, whereas at 4 weeks postinduction, these labeled cells have now dispersed throughout the OB. A similar, although more restricted, migration was also observed in hippocampus, where -Gal and NeuN double-positive neurons first appear close to the SGL 2 weeks after induction but by 4 weeks postinduction have migrated deeper into the granular layer ().
To explore the identity of the Cre-active cells, immunofluorescent double labeling was used to characterize Nes73-CreERT2;Rosa26lacZ mice 4 weeks after induction (). -Gal immunoreactivity was found in nestin and GFAP-positive neural stem/progenitor cells in the SVZ and SGL (). In the anterior part of the SVZ and SGL, DCX-positive neural progenitors also showed Cre activity (). In addition, a majority of the cells in the RMS express both -Gal and DCX (). Furthermore, NeuN-positive mature neurons that also retained -Gal immunoreactivity could be found in the HP and OB (). A small number of GFAP-positive astrocytes in the OB and the corpus callosum (CC) also expressed the reporter gene -Gal (), indicating the presence of Cre activity in multiple cell types in the NSC lineage. This result is consistent with recent quantitative lineage tracing studies (Lagace et al., 2007).
The significant amount of Cre activity induced in anterior cerebellum of adult mice was unexpected (). shows a representative eight-week-old brain from a mouse that was induced with tamoxifen at 4 weeks of age. The -Gal positive cells were mostly NeuN-positive inner granular layer (IGL) granule cells and Bergmann glia that extend long processes to the surface of the cerebellum (). Consistent with previous reports that Bergmann glia express NSC markers such as nestin and Sox2 (Mignone et al., 2004; Sottile et al., 2006), we found that Cre-active Bergmann glia also expressed the NSC marker nestin (). However, the Cre-ERT2 fusion transgene was also expressed in some Sox2-negative cells in the IGL (, middle panel), suggesting potential aberrant expression of the Nestin-CreERT2 transgene. Mild but reproducible tamoxifen-induced Cre activity was also observed in the piriform cortex (), which has also been reported to be a potential neurogenic region (Pekcec et al., 2006). We next assessed tamoxifen-induced Cre activity in other regions using whole mount X-gal staining, and found that the dorsal root ganglia (DRG) but not the spinal cord showed Cre activity (). Histologic examination revealed that less than half of the DRG neurons undergo Cre-mediated recombination (). In addition, Cre activity was detected in the optic nerve and trigeminal ganglia in mice induced at neonatal (, middle panel) or adult stages (, right panel). Collectively these data indicate that the nestin promoter/enhancer employed to generate this tamoxifen inducible transgene, exhibits remarkable fidelity to the endogenous neural expression with only a few potential sites of discrepancy.
Detailed analysis of traditional Nestin-Cre transgenic lines has revealed Cre activity outside the CNS, for example, in the kidney and in somite-derived tissues (Dubois et al., 2006). To determine whether Cre activity in the Nes73-CreERT2 mice was restricted to the nervous system, Nes73-CreERT2;Rosa26lacZ mice were induced for 5 days starting at P0 and analyzed at 8 weeks of age by whole-mount X-gal staining of internal organs including the heart, lung, liver, thymus, spleen, kidney, pancreas and stomach. With the exception of the esophagus, where neonatal but not adult exposure to tamoxifen induced Cre activity (, Supp. Info. Fig. 3) and stomach, where spontaneous lacZ activity is present in controls (, Supp. Info. Fig. 3) (Kwon et al., 2006), we found no evidence of obvious reporter expression in the absence or presence of tamoxifen (see ).
Cre activity is not observed in internal organs. Nes73-CreERT2;Rosa26lacZ mice were treated with vehicle (Veh) or tamoxifen (Tmx) at P0 for 5 days. Different organs were then dissected out at 8 weeks and subjected to whole mount X-gal staining. Endogenous ...
The rediscovery of neurogenesis in the adult brain has led to reawakened interest in the role of new neurons in the mature brain. The SVZ is a major site of neurogenesis for OB interneurons, although emerging evidence suggests additional roles. In the hippocampus, neurogenesis has been implicated in mood modulation and in learning and memory (Li et al., 2008; Lie et al., 2004; Zhao et al., 2008). On the dark side, stem/progenitor cells in the CNS have been implicated as the source of glioblastoma (Kwon et al., 2008; Sanai et al., 2005; Zhu et al., 2005). Specific ablation or activation of genes implicated in hippocampal function and in glioma can be achieved with our tamoxifen-inducible Cre transgene and we have developed successful models of both SVZ stem/progenitor cell-dependent induction of glioma and hippocampal stem/progenitor cell-dependent antidepressant insensitive mice using this tamoxifen-inducible Cre mouse line (Li et al., 2008; Llaguno et al., submitted).
Still, there is much to be learned about the precise role of neural stem cells in normal brain function and in associated pathologies. For example, in this report we describe novel sites of nestin-Cre recombinase activity. Whether this activity identifies previously undetected sites of neurogenesis or simply ectopic Cre expression remains to be rigorously determined. Of note, a second, independently derived transgenic line, Nes8-CreERT2, shows a similar pattern of inducible expression (data not shown) leading us to favor the conclusion that the expression outside the SVZ and SGZ is not due to position effects at the site of transgene insertion but rather is a reflection of the properties of the transgenic construct. Stem cells have been isolated from neonatal cerebellum and they are reported to be prominin/CD133-positive and Math1-negative (Klein et al., 2005; Lee et al., 2005). We observe Cre activity in the cerebellum from E17.5 through 8 weeks of age. Although diminishing over time, a clear gradient is observed that becomes progressively more anterior. The lacZ positive cells resulting from activation of the Rosa26 reporter possess the characteristic morphology of granule cells. In adult cerebellum, the Bergmann glia retain a morphology reminiscent of radial glia which can generate neurons and adult NSCs during brain development (Gotz and Barde, 2005; Merkle et al., 2004). In addition, Bergmann glia still express stem cell markers such as Sox2 and nestin (Mignone et al., 2004; Sottile et al., 2006). On the other hand, only rarely have cells with BrdU incorporation been observed in adult cerebellum, even after growth factor infusion (Grimaldi and Rossi, 2006). We also found that a number of cells in the anterior cerebellum targeted 2 days after acute tamoxifen administration were positive for NeuN but not GFAP or nestin (Supp. Info. Fig. 4), suggesting that the cre activity in the IGL was more likely due to promoter leakiness (Supp. Info. Fig. 4). Further study is needed to resolve this issue.
A series of similar inducible Nestin-Cre transgenes has recently been reported, although the extent of expression over time and expression outside the nervous system was not described (Supp. Info. Table 1) (Balordi and Fishell, 2007; Burns et al., 2007; Imayoshi et al., 2006; Kuo et al., 2006; Lagace et al., 2007). Eisch and co-workers recently described a tamoxifen-inducible Cre transgenic mouse line with no obvious Cre activity in the cerebellum upon tamoxifen induction (Lagace et al., 2007). The fact that our transgenic construct included only intron 2 of the nestin gene whereas their construct contained nestin exons 13 could account for this discrepancy (Zimmerman et al., 1994). It is possible that our more limited nestin construct might lack cerebellar-specific repressor sequences. Another potentially significant variation is the use of a Rosa26lacZ reporter line versus the Rosa26YFP reporter used by Lagace et al. (2007). Both the sensitivity of the reporter and perhaps the recombinogenic efficiency could in principle differ, leading to these discrepancies. We also observe Cre activity in the adult piriform cortex. This is in accordance with previous reports of BrdU incorporation in this region, leading to the suggestion of additional neurogenic niches (Pekcec et al., 2006).
We examined our mice for leakiness as well as for inducible transgene expression in the peripheral nervous system (PNS) and multiple organs. In contrast to many other Nestin reporter transgenic mice (Day et al., 2007; Dubois et al., 2006; Gleiberman et al., 2005; Li et al., 2003; Ueno et al., 2005), we found no evidence of obvious leakiness or of inducible transgene activation outside the CNS except in the PNS, where inducible expression was found both in the DRG and trigeminal ganglion, and in the esophagus. It is possible that our Nestin-CreERT2 transgene has a more restricted expression pattern or that the tamoxifen induction efficiency is lower in certain tissues. In addition, whole mount X-gal staining of the organs makes it difficult to capture rare Cre-positive cells if they do exist. DRG have been used to culture neurospheres (Li et al., 2007), and it will be of interest to determine whether our transgene is active in these progenitor cells, which would provide supportive evidence for the existence of additional neural stem/progenitor niches. Subsequent detailed lineage tracing of the Cre expressing cells will more clearly address this issue.
A 2.0 kb fragment of CreERT2 and SV40 polyA sequence of the pCre-ERT2 vector (Feil et al., 1997) were amplified using a PCR technique that also generated 5 Not1 and 3 Spe1 sites. After enzymatic digestion, purified fragment was ligated to an 8.9 kb fragment from pNerv (Panchision et al., 2001; Yu et al., 2005) digested with Not1 and Xba1. The resulting pNes-CreERT2 construct contains a 5.6 kb rat nestin 5 genetic element from pNerv, a 2.0 kb CreERT2 and SV40 polyA sequence from pCre-ERT2 and a 668 bp of reversed second intron of rat nestin from pNerv (). After Sal1 digestion, an 8.3 kb band was purified and microinjected into the pronuclei of fertilized eggs from B6D2F1 mice. Among 28 pups born after two rounds of transgenic injection, six contained the transgene, and four of them transmitted to germline. Rosa26lacZ mice were obtained from Jackson Laboratories (Bar Harbor, ME), Rosa26YFP mice were kindly provided by Dr. Jane Johnson. All the mice were maintained in a mixed genetic background of C57BL/6, SV129 and B6/CBA. Nestin73-CreERT2; Rosa26lacZ mice were generated by crossing male Nestin-CreERT2 mice with female Rosa26lacZ mice. Genotyping of the mice was performed as described previously (Kwon et al., 2006). All mouse protocols were approved by the Institutional Animal Care and Research Advisory Committee at the University of Texas Southwestern Medical Center.
Tamoxifen (Sigma-Aldrich, St. Louis, MO) was dissolved in a sunflower oil (Sigma-Aldrich, St. Louis, MO)/ethanol mixture (9:1) at 6.7 mg/ml. For initial screening of the embryonic induction of the transgenic lines, 150-l tamoxifen (1 mg) or vehicle (sunflower oil/ethanol mixture only) was injected intraperitoneally into pregnant mice at embryonic day E12.5 (E12.5 hereafter). Embryos were dissected out 2 days later and subjected to X-gal staining. For in utero induction, 150-l tamoxifen (1 mg) or vehicle was injected intraperitoneally into pregnant mothers at E13.5 or E17.5, and pups were analyzed 1 month after birth. For neonatal induction, 12.5-l tamoxifen (83.5 mg/kg body weight) or vehicle per gram of mouse body weight was injected into lactating mothers (tamoxifen can be delivered to pups through the mothers milk) at P0 or P7, once a day for 5 days and the pups were analyzed 4 weeks after the first induction. For induction in adult mice, 12.5-l tamoxifen (83.5 mg/kg) or vehicle per gram of body weight was injected intraperitoneally into 4- or 8-week-old mice twice a day for five consecutive days and then analyzed 2 or 4 weeks after the first induction.
Mice were dissected and perfused as previously described (Kwon et al., 2006). For whole mount X-gal staining, the embryos or organs were carefully dissected out, washed with phosphate-buffered saline (PBS), and then fixed in 2% (w/v) paraformaldehyde (PFA; in PBS) for 1 h at 4C. Postnatal brains were postfixed in 2% PFA overnight (O/N) at 4C, embedded in 2.5% chicken albumin sagittally or coronally, and then cut into 50-m thick sections by vibratome (Leica, Nussloch, Germany). Every fifth sagittal section or 12th coronal section was chosen to perform X-gal staining and comparable sections were selected for further immunostaining according to the X-gal staining result. X-gal staining of organs and sections was performed as described (Kwon et al., 2006).
Four Nestin73-CreERT2;Rosa26YFP mice were induced at 4 weeks of age as described above and perfused with 2% PFA at 6 weeks of age. The brains were dissected out, postfixed in 4% PFA O/N at 4C, processed and embedded in paraffin blocks. Five-m thick sagittal sections were cut until the lateral ventricle was gone. H&E staining was performed on every fifth slide to determine comparable sections. Every 10th of comparable sections was subjected to GFP (Aves Labs, Tigard, OR) and Sox2 (Chemicon, Temecula, CA) immunofluorescence staining, and three random regions of the frontal SVZ of each section were selected for counting. The efficiency was determined by the percentage of GFP (mean 203)/Sox2 (mean 270) double-positive cells out of the total Sox2-positive cells in SVZ.
Free-floating immunofluorescence staining was performed on 50-m thick sections. Antibodies used for the staining were against -galactosidase (ICN, Aurora, OH), GFAP, nestin (BD Biosciences, Bedford, MA), doublecortin (Santa Cruz Biotechnology, Santa Cruz, CA), NeuN (Chemicon, Temecula, CA), Mash1 (BD Biosciences, Bedford, MA), S100 (Sigma-Aldrich, St. Louis, MO). Alexar-488 or Alexar-555 conjugated goat anti-mouse or anti-rabbit (Molecular Probes, Eugene, OR) and Cy2 or Cy3 donkey anti-goat, anti-rabbit antibodies (Jackson Immunoresearch, West Grove, PA) were used to visualize primary antibody staining. Images were taken on a Zeiss LSM 510 confocal microscope (Carl Zeiss, Jena, Germany). For ER and Sox2 staining, 5-m thick paraffin sections were first stained with estrogen receptor antibody (Lab Vision, Fremont, CA) and visualized by DAB substrate with nickel solution (Vector Laboratories, Burlingame, CA). The slides were then washed with PBS three times, stained with Sox2 antibody (Chemicon, Temecula, CA), and visualized by Vector NovaRED (Vector Laboratories, Burlingame, CA). Images were taken with a Nikon 2000 CCD camera (Nikon, Japan). All images were assembled using Adobe Photoshop CS and Illustrator CS (Adobe Systems Incorporated, San Jose, CA).
We thank Steven Kernie for providing pNerv plasmid, Jane Johnson and Frank Costantini for providing Rosa26YFP mice, Steven McKinnon, Shirley Hall, and Linda McClellan for technical assistance, Renee McKay for reading the manuscript, and Jane Johnson, James Battiste, Jing Zhou, and Yun Li for discussion and suggestions.
Additional Supporting Information may be found in the online version of this article.
View post:
Inducible Site-Specific Recombination in Neural Stem ...
- The Stem Cell Center at Texas Heart Institute at St. Luke's [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- The Ice Bucket Challenges stem cell controversy [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- New gene editing method corrects muscular dystrophy in mice [Last Updated On: August 25th, 2014] [Originally Added On: August 25th, 2014]
- TD Jakes, Perry Noble, Nick Vujicic and Jentezen Franklin Accept ALS 'Ice Bucket Challenge,' Call Out Rick Warren, Ed ... [Last Updated On: August 30th, 2014] [Originally Added On: August 30th, 2014]
- Broach Foundation Commits $5 Million to Brain Cancer Research [Last Updated On: September 12th, 2014] [Originally Added On: September 12th, 2014]
- Could stem cell jab help elderly blind see again? [Last Updated On: October 15th, 2014] [Originally Added On: October 15th, 2014]
- UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis [Last Updated On: October 31st, 2014] [Originally Added On: October 31st, 2014]
- 'Wound response' of cancer stem cells may explain chemo-resistance in bladder cancer [Last Updated On: December 4th, 2014] [Originally Added On: December 4th, 2014]
- Adult Stem Cell Banks and Clinics Marketing Stem Cell ... [Last Updated On: December 17th, 2014] [Originally Added On: December 17th, 2014]
- Howe shows steady progress following stem cell treatment [Last Updated On: December 20th, 2014] [Originally Added On: December 20th, 2014]
- Clinical Trials and Current Research at the Stem Cell ... [Last Updated On: December 24th, 2014] [Originally Added On: December 24th, 2014]
- Stem Cell Injection Houston | Stem Cell Houston Texas [Last Updated On: January 5th, 2015] [Originally Added On: January 5th, 2015]
- New Pathway for Stalling BRCA Tumor Growth Revealed [Last Updated On: February 3rd, 2015] [Originally Added On: February 3rd, 2015]
- Scientists Identify Prostate Cancer Stem Cells Among Low ... [Last Updated On: February 11th, 2015] [Originally Added On: February 11th, 2015]
- Fluorescent probe for labeling mitochondria helps scientists study fat-burning brown adipose tissue [Last Updated On: February 18th, 2015] [Originally Added On: February 18th, 2015]
- Xiling Shen: An Engineering Approach to Biomedical Challenges [Last Updated On: February 24th, 2015] [Originally Added On: February 24th, 2015]
- A single target for microRNA regulation [Last Updated On: March 3rd, 2015] [Originally Added On: March 3rd, 2015]
- CPRIT Awards Faculty $11.5 Million for Recruitment and Research in Brain and Bone Cancer, Biology, and Immunotherapy [Last Updated On: March 7th, 2015] [Originally Added On: March 7th, 2015]
- MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia [Last Updated On: April 3rd, 2015] [Originally Added On: April 3rd, 2015]
- Mesquite Texas Stem Cell Research | Mesquite TX Stem Cell ... [Last Updated On: July 2nd, 2015] [Originally Added On: July 2nd, 2015]
- Why chemotherapy doesn't work - NaturalNews.com [Last Updated On: November 23rd, 2016] [Originally Added On: November 23rd, 2016]
- 7th International Conference on Stem Cells and Cancer ... [Last Updated On: November 27th, 2016] [Originally Added On: November 27th, 2016]
- Lung Institute | Stem Cell Treatment in Texas [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Texas gives green-light for experimental stem-cell ... [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- Zika Virus Targets and Kills Brain Cancer Stem Cells - UC San Diego Health [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- New therapy could protect diabetic bones - Science Magazine [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- Army medic donates bone marrow to stranger in need - Hawaii Army Weekly [Last Updated On: September 8th, 2017] [Originally Added On: September 8th, 2017]
- Use of Genetically Modified Stem Cells in Experimental ... [Last Updated On: September 24th, 2017] [Originally Added On: September 24th, 2017]
- Rejuvenating gonads with stem cells - Fertility Lab Insider [Last Updated On: October 15th, 2017] [Originally Added On: October 15th, 2017]
- Kim Kardashian Micro Needling PRP with Stem Cells - Dermapen [Last Updated On: June 19th, 2018] [Originally Added On: June 19th, 2018]
- The Stem Cell Institute of Texas | San Antonio, TX [Last Updated On: July 6th, 2018] [Originally Added On: July 6th, 2018]
- Stem Cell Therapy Doctor | Westlake Austin Texas [Last Updated On: August 25th, 2018] [Originally Added On: August 25th, 2018]
- Shooting Up Stem Cells With Ben Greenfield The Down The ... [Last Updated On: September 16th, 2018] [Originally Added On: September 16th, 2018]
- HB810 | Right to Try Law | Texas Stem Cell Law | StemGenex [Last Updated On: October 13th, 2018] [Originally Added On: October 13th, 2018]
- Dallas, Texas, Stem Cells Treatment, Legal, Ft. Worth ... [Last Updated On: November 16th, 2018] [Originally Added On: November 16th, 2018]
- Texas | The Stem Cellar [Last Updated On: December 5th, 2018] [Originally Added On: December 5th, 2018]
- Four Types of Stem Cells - Texas Right to Life [Last Updated On: December 15th, 2018] [Originally Added On: December 15th, 2018]
- Stem Cell Doctor Dallas Dr. Darcy Brunk | Dallas, Plano ... [Last Updated On: January 25th, 2019] [Originally Added On: January 25th, 2019]
- Neuropathy & Pain Centers of Texas - Stem Cells & Neuropathy [Last Updated On: February 6th, 2019] [Originally Added On: February 6th, 2019]
- Stem Cell Treatment Center in Dallas, Texas | Stem Cell ... [Last Updated On: March 17th, 2019] [Originally Added On: March 17th, 2019]
- Our Doctors - Knee Stem Cells [Last Updated On: March 17th, 2019] [Originally Added On: March 17th, 2019]
- Stem Cell Rejuvenation Therapy | Totalhormonegenetherapy.com [Last Updated On: April 15th, 2019] [Originally Added On: April 15th, 2019]
- Fort Worth Stem Cells | Neuropathy and Pain Centers of Texas [Last Updated On: April 15th, 2019] [Originally Added On: April 15th, 2019]
- Houston, Texas Stem Cell Transplants, Richmond, Sugar Land ... [Last Updated On: April 21st, 2019] [Originally Added On: April 21st, 2019]
- Arlington Stem Cells | Neuropathy & Pain Centers of Texas [Last Updated On: May 1st, 2019] [Originally Added On: May 1st, 2019]
- Keller, TX Stem Cells | Neuropathy & Pain Centers of Texas [Last Updated On: May 31st, 2019] [Originally Added On: May 31st, 2019]
- Fast Facts: Stem Cells 101 Vital Record [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- STEM CELL THERAPY & TREATMENTS Texas Regional Health [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- Comparing Mymetics (OTCMKTS:MYMX) & Crispr Therapeutics (OTCMKTS:CRSP) - TechNewsObserver [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- A breakthrough in the battle against citrus greening - Gainesville Sun [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Stem cells regrow leg's long bones - WNDU-TV [Last Updated On: September 22nd, 2019] [Originally Added On: September 22nd, 2019]
- Interview: BIOLIFE4D is The First US Company to Bioprint a Mini-Heart (for Cardiotoxicity Testing) - 3DPrint.com [Last Updated On: September 24th, 2019] [Originally Added On: September 24th, 2019]
- Nivolumab as an addition to frontline therapy of AML in younger patients - AML Global Portal [Last Updated On: September 24th, 2019] [Originally Added On: September 24th, 2019]
- Incoming Faculty Bring New Areas of Research to Rensselaer - Rensselaer Polytechnic Institute [Last Updated On: September 24th, 2019] [Originally Added On: September 24th, 2019]
- Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 - JD Supra [Last Updated On: December 18th, 2019] [Originally Added On: December 18th, 2019]
- El Paso scientists team up for heart research project at the International Space Station - KVIA El Paso [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Stem Cell Therapy for Joints & Spine in Austin Texas [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- El Paso scientists to deliver 3D bioprinted miniature hearts to the ISS - 3D Printing Industry [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- Recombinetics Announces Collaboration with University of Texas Southwestern to Advance Regenerative Medicine Through Therapeutic Cell, Tissue, and... [Last Updated On: February 27th, 2020] [Originally Added On: February 27th, 2020]
- Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com [Last Updated On: February 27th, 2020] [Originally Added On: February 27th, 2020]
- What to do in Madison: March 2-8, 2020 - The Bozho [Last Updated On: March 2nd, 2020] [Originally Added On: March 2nd, 2020]
- Texas A&M Researcher Named To National List Of Inspiring Black Scientists - Texas A&M University [Last Updated On: March 2nd, 2020] [Originally Added On: March 2nd, 2020]
- Jimbo Fisher's Kidz1stFund, Aggie Corps of Cadets team up for Be the Match bone marrow donor registry drive - Bryan-College Station Eagle [Last Updated On: March 2nd, 2020] [Originally Added On: March 2nd, 2020]
- How industry hopes to take on COVID-19 - Bioprocess Insider - BioProcess Insider [Last Updated On: March 8th, 2020] [Originally Added On: March 8th, 2020]
- Meng Hsieh, Andrew Shubin - The New York Times [Last Updated On: March 8th, 2020] [Originally Added On: March 8th, 2020]
- Pfizer, NYU working on innovative coronavirus vaccine that could be ready by end of summer - NBC News [Last Updated On: May 7th, 2020] [Originally Added On: May 7th, 2020]
- South Sound Community Bands Together To Save Local Lives - southsoundtalk.com [Last Updated On: May 7th, 2020] [Originally Added On: May 7th, 2020]
- UT Student Awarded Prestigious Astronaut Scholarship - UT News | The University of Texas at Austin [Last Updated On: June 9th, 2020] [Originally Added On: June 9th, 2020]
- FTC ramps up enforcement with new wave of warning letters - NutraIngredients-usa.com [Last Updated On: June 9th, 2020] [Originally Added On: June 9th, 2020]
- Who's to blame? These three scientists are at the heart of the Surgisphere COVID-19 scandal - Science Magazine [Last Updated On: June 9th, 2020] [Originally Added On: June 9th, 2020]
- Texas Stem Cell Law Opens Door for Controversial Treatments [Last Updated On: June 11th, 2020] [Originally Added On: June 11th, 2020]
- Tau: Why Alzheimer's Worsens Fast in Some, Slowly in Others - Alzforum [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- Scholarly Perspectives on COVID-19, Part 1: This Was Only a Matter of Time - Southern Newsroom [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring's Plinabulin - BioSpace [Last Updated On: June 23rd, 2020] [Originally Added On: June 23rd, 2020]
- STEM CELLS | VitaDrip IV Therapy | Texas [Last Updated On: June 26th, 2020] [Originally Added On: June 26th, 2020]
- Biotechnology could change the cattle industry. Will it succeed? - Salon [Last Updated On: September 8th, 2020] [Originally Added On: September 8th, 2020]
- Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma - Science... [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West [Last Updated On: October 21st, 2020] [Originally Added On: October 21st, 2020]
- Dr. Daisy Ayim, Cosmetic Surgeon, ObGyn, Business Owner and Entrepreneur, Is Revolutionizing The Integration Of Women's Health And Cosmetic Care -... [Last Updated On: October 31st, 2020] [Originally Added On: October 31st, 2020]
- BrainStrom Cell Therapeutics (NASDAQ:BCLI) Enters Agreement With Catalent (NYSE:CTLT) For Manufacture Of Its NurOwn Cell Therapy - BP Journal [Last Updated On: October 31st, 2020] [Originally Added On: October 31st, 2020]